Since its inception, OBD has focused on:
-
Bringing the EpiSwitch™ technology and Company reference laboratory to the highest standards of quality control and now holds ISO 13485 and ISO 9001 certification.
-
Exploiting the unique potential of the EpiSwitch™ technology by developing high clinical utility tests for breast cancer, prostate cancer, malignant melanoma and liver cancer.
-
Extending the Company’s proprietary position, securing newly generated intellectual property and technical know-how.
-
Licensing the technology to third parties worldwide.
